Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced that YESINTEK™ (ustekinumab-kfce) is now ...

YESINTEK is approved for Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis, offering a ...

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis ...

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Biotechnology firm Biocon Ltd on Monday (February 24) said its unit Biocon Biologics announced the US market availability of ...

Biocon Biologics has introduced a biosimilar drug, YESINTEK, in the U.S. for treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. The launch represents a commitment to ...

MUMBAI:  Biocon Biologics Ltd has announced the US launch of Yesintek  (ustekinumab-kfce), one of the first biosimilars to Janssen's Stelara® to enter the American market. The biosimilar, approved by ...